^
    Back
    Association details:
    Biomarker:CTLA4 overexpression
    Cancer:Triple Negative Breast Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Future Oncol
    Title:

    Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response

    Published date:
    02/02/2022
    Excerpt:
    We aimed to develop a new signature based on immune-related genes to predict prognosis and response to immune checkpoint inhibitors in patients with triple-negative breast cancer (TNBC)....PD-1, PD-L1, PD-L2 and CTLA4 gene expression was higher in the low-risk group, suggesting IPRS could predict the response to immune checkpoint inhibitors.
    DOI:
    10.2217/fon-2021-0600